The Global Diabetic Neuropathy Treatment Market is expected to cross USD 5.80 Billion by 2025 at a CAGR of 5.1%.
The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.
Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.
The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8359
- Growing global geriatric population.
- Change in lifestyle habits leading to bad posture, which is increasing the prevalence of diabetic neuropathy disorder.
- Increasing research and development of new drugs to treat diabetic neuropathy disorder.
- Rising prevalence of diabetic neuropathy. For example, the prevalence of diabetic neuropathy in the fiscal year 2000 to 2030 will reach up to 366 million people in the US.
- Rising awareness of advanced treatments for diabetic neuropathy.
- Launch of a new medication to manage the symptoms of chronic diabetic neuropathy.
- High treatment costs.
- Availability of alternative therapies such as traditional medicine and physiotherapy.
- Need for specialized equipment to diagnose and treat diabetic neuropathy.
The global diabetic neuropathy treatment market has been segmented based on disorder, treatment, and end user.
The market, based on disorder, has been divided into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. The peripheral neuropathy segment is likely to be the largest during the review period due to a growing aging population and increasing prevalence of peripheral neuropathy globally. Around 1.3 million Americans are diagnosed with peripheral neuropathy every year. The autonomic neuropathy segment is predicted to be the fastest-growing due to the rising prevalence of the disorder in the elderly population.
The global diabetic neuropathy treatment market has been segmented, on the basis of treatment, into drugs, transcutaneous electrical nerve stimulation (TENS), and others. The drugs segment is expected to hold the majority share of the market. The drugs help increase muscle strength and quicken the recovery process. The transcutaneous electrical nerve stimulation segment is expected to be the fastest-growing due to the increasing use of this treatment for diabetic neuropathy. The cost of the treatment is also less as compared to other treatment types.
The end user segments of the market are hospitals and clinics, retail pharmacy, online pharmacy, and others. The hospitals and clinics segment is expected to hold the largest share of the market as these centers are the primary locations for patients receiving treatment and surgery.
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of diabetic neuropathy and rising per capita healthcare expenditure. The diabetic neuropathy treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European diabetic neuropathy treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The diabetic neuropathy treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of diabetic neuropathy and raising awareness about the treatment methods, the market in Asia-Pacific is expected to be the fastest-growing. The diabetic neuropathy treatment market in the Middle East & Africa has been divided into the Middle East and Africa.
- Abbott Laboratories (US)
- Hoffmann-La Roche Ltd (Switzerland)
- Eli Lilly and Company (US)
- Johnson & Johnson (US)
- GlaxoSmithKline Plc (UK)
- Lupin Limited (India)
- Glenmark Pharmaceuticals Limited (India)
- Depomed, Inc. (US)
- Astellas Pharma Inc (Japan)
- Pfizer Inc (US)
- MEDA Pharma GmBH & Co. KG (Germany)
Browse Premium Research Report with Detailed Tables and Figures @ https://www.marketresearchfuture.com/reports/diabetic-neuropathy-treatment-market-8359
Detailed Table of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
Send an Enquiry @ https://www.marketresearchfuture.com/enquiry/8359
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar